• Wed news: BioNTech buying Biotheus. FDA’s Califf lists hopes for his successor. Amgen loses $12B market cap from hidden spreadsheet tab. TRex Bio raises $84M. London is Europe’s life science capitol. See more on our front page

FDA Approves Another Weight Loss Drug

Quote

Anonymous

Guest
February 22, 2012 (Updated February 23, 2012) (Silver Spring, Maryland) — The Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee [1,2] voted overwhelmingly in favor of approving the obesity drug Qnexa (Vivus, Mountain View, CA), a combination of phentermine and controlled-release topiramate [3].

If measly lorcaserin even gets approved by a super slim margin, it will have to compete against this one before it even has a chance. Once again Eisai shows what a shining star it is in business and product development. And it only tool a $50 Million deposit.

All executives please dont forget: "Its all the reps' fault!"
 




Anonymous said:
February 22, 2012 (Updated February 23, 2012) (Silver Spring, Maryland) — The Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee [1,2] voted overwhelmingly in favor of approving the obesity drug Qnexa (Vivus, Mountain View, CA), a combination of phentermine and controlled-release topiramate [3].

If measly lorcaserin even gets approved by a super slim margin, it will have to compete against this one before it even has a chance. Once again Eisai shows what a shining star it is in business and product development. And it only tool a $50 Million deposit.

All executives please dont forget: "Its all the reps' fault!"
Click to expand...

This is old news and it is a great sign for Eisai. You should be thankful for this great news.
 












I want to get a job in business development at any other company and then engage Eisai in a negotiation. I could lie by the pool while they tripped over themselves to send term sheets agreeing to the most ridiculous things imaginable.
 




























Anonymous said:
February 22, 2012 (Updated February 23, 2012) (Silver Spring, Maryland) — The Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee [1,2] voted overwhelmingly in favor of approving the obesity drug Qnexa (Vivus, Mountain View, CA), a combination of phentermine and controlled-release topiramate [3].

If measly lorcaserin even gets approved by a super slim margin, it will have to compete against this one before it even has a chance. Once again Eisai shows what a shining star it is in business and product development. And it only tool a $50 Million deposit.

All executives please dont forget: "Its all the reps' fault!"
Click to expand...
I have take Topamax(topiramate) to prevent Migraines for nearly 15 years now. One of the side effects is weight loss. I have a very small appetite. Phentermine did not have to be combined with Topamax because Topamax works so well by itself. Another side effect of Topamax is memory loss. I often forget to make my calls every day!!!!
 




































Top Bottom
Back
Quote